MannKind Corporation to Participate in Upcoming Investor Conferences
MannKind Corporation announced that its CEO and CFO will provide business updates at two upcoming investor conferences in London.
Stocks · News reference
MannKind Corporation reported Q3 2026 financial performance and provided strategic outlooks, highlighting growth from new product launches and the acquisition of SC Pharma.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
MannKind Corporation announced that its CEO and CFO will provide business updates at two upcoming investor conferences in London.
RBC Capital Markets increased its price target for MannKind Corporation to $5.00 from $4.75 while maintaining a "Sector Perform" rating.
MannKind Corporation announced its financial results for the third quarter of 2026, highlighting the commercial progress of Furoscix ReadyFlow and Afrezza.
MannKind Corporation announced it will release its third quarter 2026 financial results after market close on November 5, 2026, followed by a conference call.
Cantor Fitzgerald has reaffirmed its $8.00 per share price target for MannKind Corporation.